News | July 06, 2024
Biogen completes acquisition of HI-Bio
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Investment is additive to KKR’s existing health care growth strategy
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
The agreement will facilitate the establishment of the IITK-UB Joint Center of Excellence in Biomedicine and Bioengineering
Essex enriches and complements Emmes’ services
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
